Abstract
Leukotriene B4 (LTB4) is a potent lipid mediator of many inflammatory processes (1,2). In addition, elevated tissue levels of LTB4 have been reported in inflammatory diseases such as psoriasis (3) and inflammatory bowel disease (4). For these reasons, LTB4 antagonists have been developed for the treatment of several inflammatory diseases with the aim of inhibiting LTB4 receptor-mediated neutrophil functions (5–7).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
